Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Exelixis, Inc.    EXEL

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/19/2017 06/20/2017 06/21/2017 06/22/2017 06/23/2017 Date
21.6(c) 22.28(c) 24.02(c) 24.07(c) 23.78(c) Last
5 709 876 5 095 385 7 602 082 4 882 941 20 235 944 Volume
+12.15% +3.15% +7.81% +0.21% -1.20% Change
More quotes
Financials ($)
Sales 2017 361 M
EBIT 2017 63,0 M
Net income 2017 56,2 M
Finance 2017 143 M
Yield 2017 -
Sales 2018 522 M
EBIT 2018 167 M
Net income 2018 163 M
Finance 2018 292 M
Yield 2018 -
P/E ratio 2017 132,92
P/E ratio 2018 45,44
EV / Sales2017 18,8x
EV / Sales2018 12,8x
Capitalization 6 956 M
More Financials
Company
Exelixis, Inc. is a biopharmaceutical company.It engages in the developing and commercializing small molecule therapies for the treatment of cancer.The company brands include comertriq and cobimetinib.Its pipeline consists of cabozantinib, cobimetinib and Xl 888. Exelixis was founded by Corey S.... 
More about the company
Surperformance© ratings of Exelixis, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on EXELIXIS, INC.
06/20 IPSEN : and its partner Exelixis announce independent radiology committee review..
06/20 EXELIXIS, INC. : Today's Research Reports on Stocks to Watch: Exelixis and Westp..
06/19 EXELIXIS : Announces Independent Radiology Committee Review Confirms Results fro..
06/13 EXELIXIS, INC. : Today's Research Reports on Stocks to Watch: Exelixis and Opko ..
06/12 EXELIXIS : Announces Initiation of Phase 1b Trial of Cabozantinib in Combination..
06/08 EXELIXIS : to Present at the William Blair & Co. 37th Annual Growth Stock Confer..
06/08 ACHILLION PHARMACEUTICALS : A biopharmaceutical company, engages in the discover..
05/25 EXELIXIS, INC. (NASDAQ : EXEL) Files An 8-K Departure of Directors or Certain Of..
05/25 EXELIXIS, INC. : Change in Directors or Principal Officers, Submission of Matter..
05/18 EXELIXIS, INC. : Today's Research Reports on Biotech Stocks to Watch: Exelixis a..
More news
Sector news : Bio Therapeutic Drugs
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on EXELIXIS, INC. 
2013A downturn could form
More Strategies
Latest Tweets
06/23After Hours Gainers / Losers  
06/23Algo ? $BBRY $EXEL $IMGN $DYN $JUNO $MDR $ENOC $DRYS $CARA Charts @  
06/23Algo ? $RUN $IMGN $JUNO $MDR $EXEL $BZUN Charts @  
06/23Algo ? $IMMU $BLCM $ENDP $TWTR $VRX $EXEL $DRYS $CARA Charts @  
06/23Get the latest news and updates for $GS $EXEL $AAPL $CLRO $SCHN automatically..
1
More tweets
Qtime:33
News from SeekingAlpha
06/23 After Hours Gainers / Losers
06/21 3 THINGS IN BIOTECH YOU SHOULD LEARN : June 21, 2017
06/19 Independent review affirms positive mid-stage results for Ipsen and Exelixis'..
06/15 Introducing The Future Growth Portfolio
06/12 Exelixis launches early-stage study of cabozantinib/Tecentriq combo in solid ..
Advertisement
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | EXEL | US30161Q1040 | 4-Traders
Full-screen chart
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 26,2 $
Spread / Average Target 10%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael M. Morrissey President, Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Christopher J. Senner Executive VP, Chief Financial & Accounting Officer
Gisela M. Schwab Chief Medical Officer & President-Medical Affairs
Peter Lamb Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
EXELIXIS, INC.59.49%6 956
AMGEN17.98%126 856
CELGENE CORPORATION16.03%104 873
GILEAD SCIENCES-1.52%92 150
REGENERON PHARMACEUTIC..43.43%54 987
VERTEX PHARMACEUTICALS83.97%33 251
More Results